Endogenous B-type natriuretic peptide: A limb of the regulatory response to acutely decompensated heart failure

Clinical Cardiology

Volumn 31, Issue 9, 2008, Pages 407-412

  Hobbs, Robert E ^a   Mills, Roger M ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b SCIOS INC   (United States)

Author keywords

Acute coronary syndromes; Acutely decompensated heart failure; B type natriuretic peptide; Cardiovascular biochemistry; Cardiovascular pathology; Central nervous system; Heart disease; Heart failure

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ACUTE HEART FAILURE; ADRENERGIC SYSTEM; DIURESIS; DYSPNEA; HEART FAILURE; HEART PRELOAD; HOMEOSTASIS; HUMAN; PATHOPHYSIOLOGY; PULMONARY ARTERY OCCLUSION PRESSURE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASCULARIZATION;

CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; CARDIOVASCULAR SYSTEM; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM;

EID: 53049086521     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20304     Document Type: Review

References (40)

1. Chen HH, Burnett JC Jr: The natriuretic peptides in the pathophysiology of congestive heart failure. Curr Cardiol Rep 2000; 1:198-205
2. Adams KF Jr, Mathur VS, Gheorghiade M: B-type natriuretic peptide: from bench to bedside. Am Heart J 2003;145:534-546
3. Felker GM, Adams KF Jr, Konstant MA, O'Connor CM, Gheorghiade M: The problem of decompensated heart failure: nomenclature, classification, and risk stratification. Am Heart J 2003;145(2):S18-S25
4. Adams KF Jr, Lindenfeld J, Arnold JMO, Baker DW, Barnard DH, et al.: HFSA 2006 comprehensive heart failure practice guideline. J Card Fail 2006;12(1):e1-e122
5. Nieminen MS, Böhm M, Cowie MR, Drexler H, Filippatos G, et al.: Guidelines on the diagnosis and treatment of acute heart failure-full text. Eur Heart J 2005;26:384-416
6. Bocchi EA, Vilas-Boas F, Perrone S, Camano AG, Clausell N, et al.: I. Latin American Guidelines for the assessment and management of decompensated heart failure. Arq Bras Cardiol 2005;86(Suppl. III) 49-95
7. Cea LB: Natriuretic peptide family: new aspects. Curr Med Chem Cardiovasc Hematol Agents 2005;3(2):87-98
8. D'Souza SP, Davis M, Baxter GF: Autocrine and paracrine actions of natriuretic peptides in the heart. Pharmacol Ther 2004;101:113-129
9. Berkowitz R: B-type natriuretic peptide and the diagnosis of acute heart failure. Rev Cardiovasc Med 2004;5(Suppl. 4) S3-16
10. Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, et al.: Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A 2000;97(8):4239-4244
11. Houben AJHM, van der Zander K, de Leeuw PW: Vascular and renal actions of brain natriuretic peptide in man: physiology and pharmacology. Fundam Clin Pharmacol 2005;19:411-419
12. Zannad F: Acute heart failure syndromes: the 'Cinderella' of heart failure research. Eur Heart J 2005;7(Suppl. B):B8-B12
13. Chung P, Hermann L: Acute decompensated heart failure: formulating an evidence-based approach to diagnosis and treatment (Part I). Mt Sinai J Med 2006;73(2):506-515
14. de Bold AJ, Ma KK-Y, Zhang Y, Kuroski de Bold ML, Bensimon M, et al.: The physiological and pathophysiological modulation of the endocrine function of the heart. Can J Physiol Pharmacol 2001;79:705-714
15. Gardner DG: Natriuretic peptides: markers or modulators of cardiac hypertrophy? Trends Endocrinol Metab 2003;14(9):411-416
16. Goetze JP: Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. Clin Chem 2004;50(9):1503-1510
17. Luchner A, Stevens TL, Borgeson DD, Redfield M, Wei C, et al.: Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol 1998;274:H1684-H1689
18. McCullough PA, Omland T, Maisel AS: B-type natriuretic peptides: a diagnostic breakthrough for clinicians. Rev Cardiovasc Med 2003;4(2):72-80
19. Shimizu H, Masuta K, Aono K, Asada H, Sasakura K, et al.: Molecular forms of human brain natriuretic peptide in plasma. Clin Chim Acta 2002;316(1-2): 129-135
20. Shimizu H, Masuta K, Asada H, Sugita K, Sairenji T: Characterization of molecular forms of probrain natriuretic peptide in human plasma. Clin Chim Acta 2003;334(1-2): 233-239
21. Heublein DM, Huntley BK, Boerrigter G, Cataliotti A, Sandberg S, et al.: Immunoreactivity and guanosine 3′,5′-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension 2007;49:1114-1119
22. Boerrigter G, Costello-Boerrigter LC, Harty GJ, Lapp H, Burnett JC Jr; Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation. Am J Physiol Regul Integr Comp Physiol 2007;292(2):R897-R901, Epub 2000 Oct 26
23. Hawkridge AM, Heublein DM, Bergen HR III, Cataliotti A, Burnett JC Jr, et al.: Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci U S A 2005;102(48):17442-17447, published online before print as 10.1073/pnas.0508782102
24. Liang F, O'Rear J, Schellenberger U, Lungkuo T, Lasecki M, et al.: Evidence of functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 2007;49:1071-1078
25. Rademaker MT, Richards AM: Cardiac natriuretic peptides for cardiac health. Clin Sci (Lond) 2005;108:23-36
26. Hobbs RE, Mills RM, Young JB: An update on nesiritide for treatment of decompensated heart failure. Expert Opin Investig Drugs 2001;10(5):935-942
27. Silver MA: The natriuretic peptide system: kidney and cardiovascular effects. Curr Opin Nephrol Hypertens 2006;15:14-21
28. Chen HH: A state of brain natriuretic peptide deficiency or resistance or both! J Am Coll Cardiol 2007;49(10):1079-1088
29. Boerrigter G, Burnett JC Jr: Recent advances in natriuretic peptides in congestive heart failure. Expert Opin Investig Drugs 2004;13(6):643-652
30. Kubo M, Nakaya Y, Matsuoka S, Saito K, Kuroda Y: Atrial natriuretic factor and isosorbide dinitrate modulate the gating of ATP-sensitive K+ channels in cultured vascular smooth muscle cells. Circ Res 1994;74(3):471-476
31. Price JM, Hellermann A: Inhibition of cGMP mediated relaxation in small rat coronary arteries by block of CA++ activated K+ channels. Life Sci 1997;61(12):1185-1192
32. Mehra MR, Maisel A: B-type natriuretic peptide in heart failure. Diagnostic, prognostic, and therapeutic use. Crit Pathw Cardiol 2005;4:10-20
33. Forfia PR, Lee M, Tunin RS, Mahmud M, Champion H, et al.: Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. J Am Coll Cardiol 2007;49(10):1079-1088
34. Kuhn M: Structure, regulation, and function of mammalian membrane guanlyl cyclase receptors, with a focus on guanlyl cyclase-A. Circ Res 2003;93:700-709
35. Yoshimura M, Yasue H, Ogawa H: Pathophysiological significance and clinical application of ANP and BNP in patients with heart failure. Can J Physiol Pharmacol 2001;79(8):730-735
36. McBride BF, White CM: Acute decompensated heart failure: a contemporary approach to pharmacotherapeutic management. Pharmacotherapy 2003;23(8):997-1020
37. Chen HH, Burnett JC Jr: The natriuretic peptides in heart failure: diagnostic and therapeutic potentials (review). Proc Assoc Am Physicians 1999;111(5):407-416
38. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander J, et al.: Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347(3): 161-167
39. Krauser DG, Lloyd-Jones DM, Chae CU, Cameron R, Anwaruddin S, et al.: Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. Am Heart J 2005;149(4):744-750
40. Tang WHW, Girod JP, Lee MJ, Starling R, Young J, et al.: Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation 2003;108:2964